Cargando…

Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report

Immune checkpoint inhibitors can often trigger immune‐related adverse events (irAEs), such as relapse of pre‐existing interstitial pneumonia. Here, we report the case of an 88‐year‐Japanese man diagnosed with advanced lung adenocarcinoma with a high tumor proportion score of programmed death‐ligand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Motoyasu, Mori, Mikiko, Miura, Keita, Asao, Tetsuhiko, Motomura, Hiroaki, Nishino, Koichi, Ko, Ryo, Koyama, Ryo, Hayashi, Takuo, Takahashi, Kazuhisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590898/ https://www.ncbi.nlm.nih.gov/pubmed/34617405 http://dx.doi.org/10.1111/1759-7714.14185

Ejemplares similares

Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non‐small‐cell lung cancer
por: Kurokawa, Kana, et al.
Publicado: (2022)

Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study
por: Kurokawa, Kana, et al.
Publicado: (2022)

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
por: Miyashita, Yosuke, et al.
Publicado: (2020)

Prognostic differences among patients with idiopathic interstitial pneumonias with acute exacerbation of varying pathogenesis: a retrospective study
por: Kato, Motoyasu, et al.
Publicado: (2019)

Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
por: Kato, Motoyasu, et al.
Publicado: (2014)

Severe mediastinitis over a month after endobronchial ultrasound‐guided transbronchial needle aspiration
por: Kurokawa, Kana, et al.
Publicado: (2019)

Protein-losing Enteropathy Caused by Intestinal or Colonic Lymphangiectasia Complicated by Sporadic Lymphangioleiomyomatosis: A Report of Two Cases
por: Nishino, Koichi, et al.
Publicado: (2017)

Dramatic response to pembrolizumab with chemotherapy followed by salvage surgery in a lung cancer patient
por: Saito, Shunichi, et al.
Publicado: (2021)

Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines
por: Xu, Shiting, et al.
Publicado: (2023)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
por: Xu, Shiting, et al.
Publicado: (2022)

Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer
por: Han, Harry J., et al.
Publicado: (2020)

Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
por: Spalart, Valérie, et al.
Publicado: (2019)

Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab
por: Hober, Candice, et al.
Publicado: (2021)

Bevacizumab‐induced chronic interstitial pneumonia during maintenance therapy in non‐small cell lung cancer
por: Sekimoto, Yasuhito, et al.
Publicado: (2016)

Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study
por: Nakamura, Kota, et al.
Publicado: (2017)

Late relapse of ulcerative colitis presenting as tracheobronchitis: a case report
por: Okamoto, Shouichi, et al.
Publicado: (2022)

Pembrolizumab dramatically resolves choroidal metastatis from esophageal adenocarcinoma and restores vision: a case report
por: Barrett, Dianne, et al.
Publicado: (2021)

Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
por: Kageyama, Takumi, et al.
Publicado: (2022)

Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation
por: Hayakawa, Daisuke, et al.
Publicado: (2019)

Pembrolizumab in relapsed or refractory Richter syndrome
por: Armand, Philippe, et al.
Publicado: (2020)

Cerebral infarction in advanced non-small cell lung cancer: a case control study
por: Kato, Motoyasu, et al.
Publicado: (2016)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma
por: Kanamori, Koichiro, et al.
Publicado: (2023)

Pembrolizumab on pre-existing inclusion body myositis: a case report
por: Uchio, Naohiro, et al.
Publicado: (2020)

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?
por: Shimamura, Shoko Sonobe, et al.
Publicado: (2022)

Successful restart of chemotherapy in a patient with primary mediastinal nonseminomatous germ cell tumor after COVID‐19 infection
por: Tanabe, Yuki, et al.
Publicado: (2022)

Case report: Postoperative abdominal recurrence of pulmonary pleomorphic carcinoma showed a dramatic response to S-1 after pembrolizumab
por: Kojima, Yuichi, et al.
Publicado: (2021)

Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study
por: Akamatsu, Hiroaki, et al.
Publicado: (2021)

Anaphylaxis to three humanized antibodies for severe asthma: a case study
por: Jingo, Koichi, et al.
Publicado: (2020)

Discovery of a sugar-based nanoparticle universally existing in boiling herbal water extracts and their immunostimulant effect
por: Iitsuka, Hirofumi, et al.
Publicado: (2018)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
por: Li, Xin, et al.
Publicado: (2018)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Atezolizumab‐induced fulminant type 1 diabetes mellitus occurring four months after treatment cessation
por: Nishioki, Toshihiko, et al.
Publicado: (2020)

Transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: the severity of cystic lung destruction assessed by the modified Goddard scoring system as a predictor for establishing the diagnosis
por: Okamoto, Shouichi, et al.
Publicado: (2020)

Zinc‐finger E‐box‐binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib
por: Nurwidya, Fariz, et al.
Publicado: (2021)

Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report
por: Shen, Li, et al.
Publicado: (2021)

Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting
por: Kato, Motoyasu, et al.
Publicado: (2021)

Pembrolizumab-induced Myasthenia Gravis Relapse after Immunosuppressive Therapy
por: Oshima, Yuki, et al.
Publicado: (2022)

Dramatic Clinical Response of Relapsed Metastatic Extramammary Paget's Disease to Trastuzumab Monotherapy
por: Wakabayashi, S., et al.
Publicado: (2012)

Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
por: Fujimoto, Daichi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_osud1ebs9r2kpr40lidfflt6o8